Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058863 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma
A Phase 2 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 13
- Study locations
NCT01058863 is a Phase 2 study of Asthma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 72 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The trial reports 13 study locations across 8 states.
The verdict
NCT01058863, a Phase 2 study of Asthma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is examining how well a dry powder inhaler (DPI) of albuterol medication works to help adult and adolescent subjects 12 years of age and older with persistent asthma to improve lung function.
Conditions Studied
Interventions
- DRUG Albuterol Spiromax®
- DRUG ProAir® HFA
- OTHER Placebo Inhaler
Study Locations (13)
California
- Teva Clinical Study Site - Huntington Beach
- Teva Clinical Study Site - Rolling Hills Est.
- Teva Clinical Study Site - San Diego
Florida
- Teva Clinical Study Site - Margate
- Teva Clinical Study Site - Miami
Ohio
- Teva Clinical Study Site - Cincinnati
- Teva Clinical Study Site - Dayton
Oregon
- Teva Clinical Study Site - Medford
- Teva Clinical Study Site - Portland
Colorado
- Teva Clinical Study Site - Colorado Springs
Missouri
- Teva Clinical Study Site - St Louis
New Jersey
- Teva Clinical Study Site - Skillman
North Carolina
- Teva Clinical Study Site - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01058863
The ClinicalTrials.gov registry entry for NCT01058863 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Albuterol Spiromax® is the first listed.
NCT01058863 reports 13 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01058863 about?
NCT01058863 is a clinical study titled "A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma". This study is examining how well a dry powder inhaler (DPI) of albuterol medication works to help adult and adolescent subjects 12 years of age and older with persistent asthma to improve lung function.
What is the current status of trial NCT01058863?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2010-02. Estimated completion is 2010-06.
What conditions does trial NCT01058863 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01058863?
The interventions under investigation include: Albuterol Spiromax® (DRUG), ProAir® HFA (DRUG), Placebo Inhaler (OTHER).
Who is sponsoring clinical trial NCT01058863?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01058863 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.